A clinician-level review of dutasteride (Avodart) and muscle preservation strategies, covering DHT suppression, resistance training protocols, protein targets, and monitoring guidance backed by primary-source evidence.
A guide to dutasteride (Avodart) monitoring protocols for men and women aged 50 to 64, covering PSA interpretation, cardiovascular checks, hormone interactions, and safety labs at each follow-up visit.
What happens when you stop dutasteride during illness, when it's safe to restart, and exactly how to resume therapy after acute illness. guidance with primary-literature citations.
Board-reviewed guide on the dutasteride (Avodart) pre-surgery hold window: when to stop, why it matters for PSA, bleeding, and anesthesia, and how to safely restart.
A clinician-level review of dutasteride (Avodart) dosing in renal impairment, covering pharmacokinetics, mechanism of action, trial data, and practical prescribing guidance.
A clinician-level review of how dutasteride (Avodart) affects sleep architecture, including neurosteroid suppression, REM disruption, and clinical management strategies backed by primary literature.
Everything clinicians and patients need to know about switching between dutasteride, finasteride, and other 5-alpha-reductase inhibitors, with trial evidence, dosing protocols, and pharmacokinetic rationale.
A guide to dutasteride (Avodart) monitoring for men aged 18 to 29, covering labs, fertility, sexual side effects, PSA interpretation, and when to stop treatment.
A guide to dutasteride safety in young adults ages 18, 29, covering sexual side effects, fertility, mental health signals, contraindications, and monitoring protocols with primary-source citations.
When and how to safely restart empagliflozin after illness, surgery, or hospitalization. Covers sick-day rules, DKA risk, renal thresholds, and a step-by-step restart protocol backed by primary literature.
Does Jardiance (empagliflozin) affect bone density or fracture risk? A review of the clinical trial data, mechanisms, and monitoring guidance for patients and prescribers.
Does enclomiphene citrate change appetite or cravings? A clinician-level review of the mechanisms, clinical trial data, and practical guidance for men on enclomiphene therapy.
A physician-level review of the cancer risk signals associated with enclomiphene citrate, covering estrogen receptor pharmacology, published trial safety data, and how clinicians should counsel patients on off-label use for secondary hypogonadism.
A guide to enclomiphene citrate dosing in men aged 65 and older, covering starting doses, titration, renal and hepatic adjustments, fall risk, drug interactions, and monitoring protocols for secondary hypogonadism.
A deep dive into how enclomiphene citrate affects testosterone, metabolic rate, body composition, and energy expenditure, with primary-literature citations and clinical dosing guidance.
A physician-level guide to safely restarting enclomiphene citrate after acute illness, covering when to pause, how to re-titrate, and what lab values guide the decision.
A deep dive into how enclomiphene citrate affects sleep architecture, REM sleep, slow-wave sleep, and testosterone-driven circadian signaling in men with secondary hypogonadism.
A physician-level review of epitalon tetrapeptide's long-term cardiovascular effects, covering telomerase biology, oxidative stress, lipid profiles, and what Russian cohort data and preclinical trials reveal about heart health outcomes.
A safety guide for epitalon tetrapeptide use in adults aged 50 to 64, covering current evidence, contraindications, drug interactions, and monitoring recommendations.
A deep dive into how the tetrapeptide Epitalon affects sleep architecture, melatonin secretion, circadian rhythm regulation, and sleep quality in aging adults, with primary-literature citations throughout.
A clinician-level guide to switching protocols for epitalon tetrapeptide, covering mechanism, class comparisons, dosing cycles, and evidence-based transition strategies with primary-source citations.
A complete clinical monitoring guide for adults aged 18-29 using epitalon tetrapeptide, covering baseline labs, cycle tracking, fertility considerations, and safety checkpoints backed by primary research.
A clinical review of epitalon tetrapeptide safety in adults aged 18, 29, covering telomere biology, known risks, dosing considerations, fertility implications, and what current evidence does and does not support.
A guide to oral estradiol safety in geriatric patients (65+), covering cardiovascular risk, VTE, breast cancer data, drug interactions, and deprescribing thresholds.
A guide to oral estradiol missed-dose management, covering pharmacokinetics, step-by-step recovery instructions, symptom implications, and the clinical evidence behind current recommendations.
A clinician-level guide to diagnosing and correcting oral estradiol plateau and non-response in menopausal HRT, covering pharmacokinetics, lab interpretation, dose adjustments, and route-switching strategies with primary literature citations.
A clinician-level guide to the oral estradiol pre-surgery hold window: timing, thrombotic risk mechanisms, guideline recommendations, and safe restart protocols after surgery.
A deep dive into how oral estradiol affects libido, arousal, lubrication, and pain during sex, with primary-literature citations, real doses, and a clinical decision framework.
A clinician-level review of how oral estradiol affects sleep architecture, REM duration, slow-wave sleep, and sleep efficiency in menopausal women, with primary-literature citations and dosing context.
A complete guide to TRICARE coverage, formulary tier, prior authorization, step therapy, and appeal pathways for oral estradiol (estrace, generic 17-beta estradiol) for menopausal vasomotor symptoms.
A review of oral estradiol cancer risk signals across breast, endometrial, ovarian, and other cancers, distinguishing WHI trial data from guideline statements and noting where citation verification is still required.
A clinician-level review of how oral estradiol affects hair growth, hair loss, skin thickness, collagen, sebum, and wound healing, with primary-literature citations and practical dosing context.
A guide to estradiol transdermal patch safety for adults aged 30 to 49, covering cardiovascular risk, breast cancer data, clot risk, contraindications, and monitoring protocols.
Evidence-based guide to estradiol transdermal patch dosing for adults ages 50 to 64, including starting doses, titration schedules, cardiovascular risk stratification, and monitoring protocols prepared by the HealthRX.com Editorial Team.
A clinician-level review of estradiol patch pharmacokinetics covering absorption, distribution, metabolism, and excretion, with cited trial data, dose-exposure relationships, and practical prescribing implications.
A detailed guide to UnitedHealthcare coverage for estradiol transdermal patches, including formulary tiers, prior authorization criteria, step therapy requirements, and how to appeal a denial.
A guide to estradiol transdermal patch dosing for women aged 18 to 29, covering starting doses, titration, the evidence base for this age group, and how patch therapy interacts with fertility and family planning goals.
A clinician-level review of estradiol transdermal patch use in patients with autoimmune conditions, covering disease-specific risks, benefits, dosing, and monitoring protocols backed by primary literature.
What long-term transdermal estradiol use appears to do to cardiovascular risk, how that differs from oral estrogen data, and where the evidence for the patch specifically is still incomplete.
A clinician-level review of how transdermal estradiol affects memory, processing speed, and dementia risk in peri- and postmenopausal women, framed around what is established, what is plausible, and what remains unproven.
A clinician-level comparison of compounded and FDA-approved branded estradiol transdermal patches covering bioequivalence, safety data, regulatory status, cost, and how to choose the right formulation for menopausal hormone therapy.
A clinician-level guide to how heat, cold, humidity, and UV exposure affect estradiol transdermal patch adhesion, absorption, and dosing across seasons. Includes primary-literature citations, dosing guidance, and storage recommendations.
A clinician-level review of eszopiclone's long-term cardiovascular effects, covering autonomic modulation, blood pressure data, arrhythmia risk, and what prescribers should monitor in patients taking Lunesta chronically.
A clinician-level breakdown of eszopiclone (Lunesta) cost, mechanism, and head-to-head comparison with zolpidem, zaleplon, benzodiazepines, doxepin, ramelteon, suvorexant, and lemborexant. Evidence-cited. Dosing tables included.
A citation-dense guide to every clinically significant drug-drug interaction with eszopiclone (Lunesta): CYP3A4 inhibitors, CNS depressants, opioids, antifungals, and more, with specific pharmacokinetic data and management recommendations.
A clinician-level review of eszopiclone (Lunesta) and its reported effects on hair and skin, including dermatologic adverse events from FDA labeling, published trials, and real-world pharmacovigilance data.
A clinical deep-dive into AOD-9604 (HGH fragment 176-191) dosing for Hispanic and Latino patients, covering pharmacogenomics, insulin resistance phenotypes, CYP variant data, and evidence-based dose adjustment strategies.
East Asian patients metabolize atorvastatin differently due to SLCO1B1 and ABCG2 transporter variants. This article reviews what pharmacokinetic and guideline evidence actually supports about lower starting doses, and where the evidence stops and clinical judgment begins.
A deep clinical review of BPC-157 efficacy differences in East Asian patients, covering CYP2C19/CYP2D6 polymorphisms, BMI-adjusted dosing, and the current state of ethnicity-stratified trial data.
A guide to tadalafil dosing in South Asian patients, covering CYP3A4 and CYP2C9 variants, cardiovascular risk at lower BMI, drug interactions with metformin and statins, and evidence-based dose adjustment protocols.
A clinical deep-dive into dutasteride (Avodart) efficacy differences in Hispanic and Latino patients, covering pharmacogenomics, CYP enzyme variants, ethnicity-stratified trial data, and evidence-based dosing considerations.
A clinical review of whether Epitalon (epitalon tetrapeptide) works differently in East Asian patients, covering pharmacogenomic variation, dosing considerations, and what the current evidence actually shows.
A clinician-focused guide to finasteride dosing, pharmacogenomics, and efficacy evidence in Black and African ancestry patients, including SRD5A2 variant data, ethnicity-stratified trial subgroups, and practical prescribing guidance.
A guide to finasteride pharmacogenomics, dosing considerations, and safety differences in Hispanic and Latino patients, with ethnicity-stratified data, PharmGKB references, and practical prescribing guidance.
A clinical review of how finasteride performs in South Asian men with androgenetic alopecia, covering pharmacogenomics, SRD5A2 polymorphisms, ethnicity-stratified trial data, and dosing considerations for this population.
A clinical review of finasteride pharmacogenomics, dosing considerations, and safety differences in South Asian patients, with cited trial data and guideline references.
A clinically detailed review of isotretinoin safety, pharmacogenomics, and dosing considerations specific to patients of Black or African ancestry, with evidence from ethnicity-stratified data and population pharmacogenomic studies.
A guide to isotretinoin pharmacogenomics, dosing adjustments, and safety considerations specific to East Asian patients, with ethnicity-stratified data and guideline citations.
A clinically detailed review of liraglutide dosing in East Asian patients, covering pharmacokinetics, ethnicity-stratified trial data, BMI thresholds, and pharmacogenomic considerations including CYP2C19 and CYP2D6 polymorphisms.
A guide to liraglutide dosing considerations for South Asian patients, covering ethnicity-adjusted BMI thresholds, cardiovascular risk context, pharmacokinetic reasoning, and where the evidence runs out.